Therapeutic options for 5-lipoxygenase inhibitors.
暂无分享,去创建一个
[1] T. Adrian,et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] Oliver Werz,et al. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. , 2002, Biochemical pharmacology.
[3] J. Rask-Madsen,et al. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease , 2005, Agents and Actions.
[4] J. Eckman,et al. Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. , 2001, Pharmacological research.
[5] G. Wong,et al. The relation between obesity and asthmatic airway inflammation , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[6] Vilmundur Gudnason,et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.
[7] B. Persson,et al. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. , 2000, American journal of respiratory and critical care medicine.
[8] O. Werz. 5-lipoxygenase: cellular biology and molecular pharmacology. , 2002, Current drug targets. Inflammation and allergy.
[9] T. Adrian,et al. Lipoxygenase inhibitors for the treatment of pancreatic cancer , 2003, Expert review of anticancer therapy.
[10] M. Fukuda,et al. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. , 1998, Biochemical and biophysical research communications.
[11] M. Vos,et al. 5‐lipoxygenase inhibitors reduce PC‐3 cell proliferation and initiate nonnecrotic cell death , 1998, The Prostate.
[12] K. Abe,et al. Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[13] G. Feuerstein. Leukotrienes and the cardiovascular system. , 1984, Prostaglandins.
[14] E. Goetzl,et al. Heterogeneity of Human Polymorphonuclear Leukocyte Receptors for Leukotriene B4 Identification of a Subset of High Affinity Receptors That Transduce the Chemotactic Response , 1980 .
[15] C. D. Richardson,et al. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. , 1993, European journal of biochemistry.
[16] C. Myers,et al. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. , 1997, Biochemical and biophysical research communications.
[17] C. Leslie,et al. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. , 1990, The Journal of biological chemistry.
[18] S. Muro,et al. 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. , 2003, The Journal of allergy and clinical immunology.
[19] M. J. Smith,et al. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. , 1983, Annals of the rheumatic diseases.
[20] R. Murphy,et al. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Wang,et al. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. , 2004, Current cancer drug targets.
[22] P. V. D. van de Kerkhof,et al. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. , 1996, Skin pharmacology : the official journal of the Skin Pharmacology Society.
[23] N. Fusenig,et al. 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] Jilly F. Evans,et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm , 2004, Nature Medicine.
[25] R. Snyderman,et al. Targeted Disruption of the Leukotriene B4Receptor in Mice Reveals Its Role in Inflammation and Platelet-Activating Factor–Induced Anaphylaxis , 2000, The Journal of experimental medicine.
[26] T. Cohnert,et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[27] E. Silverman,et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.
[28] J. Haeggström. Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.
[29] Takao Shimizu,et al. International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor , 2004, Pharmacological Reviews.
[30] J. Rokach,et al. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. , 2005, Progress in lipid research.
[31] C. Funk,et al. The N-terminal “β-Barrel” Domain of 5-Lipoxygenase Is Essential for Nuclear Membrane Translocation* , 2001, The Journal of Biological Chemistry.
[32] R. Dixon,et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.
[33] K. Riesbeck,et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. , 2005, Cancer research.
[34] A. Wildfeuer,et al. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients , 1992, Acta neurologica Scandinavica.
[35] P. Biberfeld,et al. Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. , 1995, European journal of biochemistry.
[36] M. Fang,et al. Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib , 2005, Clinical Cancer Research.
[37] J. Eckman,et al. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. , 1998, Journal of medicinal chemistry.
[38] E. Sugikawa,et al. Identification of a Novel Human Eicosanoid Receptor Coupled to Gi/o * , 2002, The Journal of Biological Chemistry.
[39] U. Thorsteinsdóttir,et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. , 2005, American journal of human genetics.
[40] O. Werz,et al. The C2-like β-Barrel Domain Mediates the Ca2+-dependent Resistance of 5-Lipoxygenase Activity Against Inhibition by Glutathione Peroxidase-1* , 2003, Journal of Biological Chemistry.
[41] T. Adrian,et al. Multiple Signal Pathways Are Involved in the Mitogenic Effect of 5(S)-HETE in Human Pancreatic Cancer , 2003, Oncology.
[42] D. Beer,et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. , 2003, Journal of the National Cancer Institute.
[43] Jilly F. Evans,et al. International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors , 2003, Pharmacological Reviews.
[44] John I. Gallin,et al. Inflammation: Basic Principles and Clinical Correlates , 1992 .
[45] J. Palmblad,et al. Dominant Expression of the CysLT2 Receptor Accounts for Calcium Signaling by Cysteinyl Leukotrienes in Human Umbilical Vein Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[46] H. Friess,et al. THE LEUKOTRIENE RECEPTOR: BLT2R IS OVEREX-PRESSED IN PANCREATIC INTRAEPITHELIAL NEOPLASTIC LESIONS (PANINS): A NEW TARGET FOR THERAPY? , 2004 .
[47] 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. , 2005 .
[48] B. Rigas,et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. , 1995, Biochimica et biophysica acta.
[49] A. Lusis,et al. Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice , 2002, Circulation research.
[50] L. Bonewald,et al. Mice lacking 5-lipoxygenase have increased cortical bone thickness. , 1997, Advances in experimental medicine and biology.
[51] M. Yacoub,et al. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. , 1993, Cardioscience.
[52] T. Rabe,et al. Influence of 5-Lipoxygenase on in vitro Growth of Human Mammary Carcinoma Cell Line MCF-7 , 1998, Gynecologic and Obstetric Investigation.
[53] R. Simon,et al. A pilot study examining the role of zileuton in atopic dermatitis. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[54] M. Peters-Golden,et al. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] O. Rådmark. Arachidonate 5-lipoxygenase. , 2002, Journal of lipid mediators and cell signalling.
[56] J. Kutok,et al. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). , 2002, The Journal of pharmacology and experimental therapeutics.
[57] H. Magnussen,et al. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. , 1998, The European respiratory journal.
[58] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[59] M. H. Lee,et al. Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)–Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation , 1996, Molecular medicine.
[60] D. Steinhilber. 5-Lipoxygenase: enzyme expression and regulation of activity. , 1994, Pharmaceutica acta Helvetiae.
[61] J. Ajani,et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. , 2005, Carcinogenesis.
[62] J. Pelletier,et al. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. , 2002, Arthritis and rheumatism.
[63] Luís Vila,et al. Cyclooxygenase and 5‐lipoxygenase pathways in the vessel wall: Role in atherosclerosis , 2004, Medicinal research reviews.
[64] D. Bostwick,et al. Lipoxygenase‐5 is overexpressed in prostate adenocarcinoma , 2001, Cancer.
[65] Effects of synthetic peptido‐leukotrienes on bone resorption in vitro , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[66] W. Powell,et al. Effects of phorbol myristate acetate on the synthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid by human polymorphonuclear leukocytes. , 1994, Biochemistry.
[67] L. Iversen,et al. Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase. , 1993, The Journal of investigative dermatology.
[68] J. Baker,et al. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. , 1997, European journal of biochemistry.
[69] A. Hatzelmann,et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis , 2005, Agents and Actions.
[70] Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004 .
[71] W. Feldberg,et al. Liberation of histamine and formation of lysocithin‐like substances by cobra venom , 1938, The Journal of physiology.
[72] R. Mansel,et al. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.
[73] M. Yacoub,et al. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. , 1998, Circulation.
[74] L. Bonewald,et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[75] Jilly F. Evans,et al. Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate 5-Lipoxygenase–Dependent Circuits of Inflammation and Atherogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[76] O. Werz,et al. 1-Oleoyl-2-acetylglycerol Stimulates 5-Lipoxygenase Activity via a Putative (Phospho)lipid Binding Site within the N-terminal C2-like Domain* , 2005, Journal of Biological Chemistry.
[77] Robert A. Lewis,et al. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.
[78] J. Mulshine,et al. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. , 1999, Cancer research.
[79] H. Claesson,et al. Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugs , 1999, Journal of internal medicine.
[80] D. Aronoff,et al. Phosphorylation by Protein Kinase A Inhibits Nuclear Import of 5-Lipoxygenase* , 2005, Journal of Biological Chemistry.
[81] Ying Chen,et al. Inhibition of leukotriene function can modulate particulate-induced changes in bone cell differentiation and activity. , 2001, Journal of biomedical materials research.
[82] C. Rouzer,et al. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. , 1988, The Journal of biological chemistry.
[83] B. Koller,et al. Role of the 5-Lipoxygenase–activating Protein (FLAP) in Murine Acute Inflammatory Responses , 1997, The Journal of experimental medicine.
[84] S. Dahlén,et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[85] T. Meitinger,et al. ALOX5AP Gene and the PDE4D Gene in a Central European Population of Stroke Patients , 2005, Stroke.
[86] J. Maclouf,et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. , 1996, The Journal of pharmacology and experimental therapeutics.
[87] J. Saffar,et al. The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. , 1995, Bone.
[88] T. Adrian,et al. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. , 2005, Biochemical and biophysical research communications.
[89] O. Werz,et al. Induction of 5-lipoxygenase activation in polymorphonuclear leukocytes by 1-oleoyl-2-acetylglycerol. , 2003, Biochimica et biophysica acta.
[90] S. Paruchuri,et al. The Pro-inflammatory Mediator Leukotriene D4 Induces Phosphatidylinositol 3-Kinase and Rac-dependent Migration of Intestinal Epithelial Cells* , 2005, Journal of Biological Chemistry.
[91] M. Laviolette,et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.
[92] V. Coppola,et al. 5‐Lipoxygenase regulates senescence‐like growth arrest by promoting ROS‐dependent p53 activation , 2005, The EMBO journal.
[93] Y. Kawahito,et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. , 2005, Oncology reports.
[94] O. Werz,et al. A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6 , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[95] Q. Hamid,et al. 5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats. , 1998, The Journal of clinical investigation.
[96] N. Flamand,et al. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. , 2002, Molecular pharmacology.
[97] S. Charleson,et al. Leukotrienes C4 and D4 in psoriatic skin lesions. , 1985, Prostaglandins.
[98] J. Gulcher,et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.
[99] N. Nirmala,et al. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. , 2003, Molecular pharmacology.
[100] R. Murphy,et al. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. , 1992, The Journal of biological chemistry.
[101] T. Adrian,et al. A novel anti-pancreatic cancer agent, LY293111 , 2005, Anti-cancer drugs.
[102] W. Lehmann,et al. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[103] T. Moody,et al. Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] E E Schadt,et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits , 2005, Nature Genetics.
[105] J. Miyazaki,et al. Role of cytosolic phospholipase A2 in allergic response and parturition , 1997, Nature.
[106] J. Sheller,et al. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. , 1997, The American journal of physiology.
[107] O. Werz,et al. Arachidonic Acid Promotes Phosphorylation of 5-Lipoxygenase at Ser-271 by MAPK-activated Protein Kinase 2 (MK2)* , 2002, The Journal of Biological Chemistry.
[108] B. Henderson,et al. Human chaperonin 60 (Hsp60) stimulates bone resorption: structure/function relationships. , 2003, Bone.
[109] J. Ghosh,et al. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. , 2006, Biochemical and biophysical research communications.
[110] A. Black,et al. Leukotriene B4‐like material in scale of psoriatic skin lesions , 1984, British journal of pharmacology.
[111] Jing Wu,et al. Five‐lipoxygenase‐activating protein inhibitor MK‐886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax , 2004, Journal of gastroenterology and hepatology.
[112] M. Goppelt‐Struebe. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. , 1997, Biochemical pharmacology.
[113] O. Werz,et al. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. , 2002, Blood.
[114] M. Peters-Golden,et al. Protein Kinase A Inhibits Leukotriene Synthesis by Phosphorylation of 5-Lipoxygenase on Serine 523* , 2004, Journal of Biological Chemistry.
[115] G. Davı̀,et al. 5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[116] O. Werz,et al. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. , 1996, European journal of biochemistry.
[117] Anatoly L. Mayburd,et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. , 2005, Cancer research.
[118] H E Morton,et al. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. , 1990, The Journal of biological chemistry.
[119] P. Arner,et al. ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance , 2006, International Journal of Obesity.
[120] P. Young,et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.
[121] Takao Shimizu,et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis , 1997, Nature.
[122] Y. Kanaoka,et al. Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses1 , 2004, The Journal of Immunology.
[123] C. Owman,et al. Cloning of cDNA encoding a putative chemoattractant receptor. , 1996, Genomics.
[124] J. Zakrzewski,et al. Leukotriene B4 and oral cancer. , 1990, The British journal of oral & maxillofacial surgery.
[125] O. Werz,et al. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. , 1998, Molecular pharmacology.
[126] D. Steinhilber. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. , 1999, Current medicinal chemistry.
[127] O. Werz,et al. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[128] L. Bonewald,et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. , 1993, The Journal of biological chemistry.
[129] C. Myers,et al. Lipoxygenase Inhibition in Prostate Cancer , 1999, European Urology.
[130] H. Degreef,et al. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. , 1990, Journal of the American Academy of Dermatology.
[131] Nicholas Schork,et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.
[132] R. McMillan. Leukotrienes in respiratory disease. , 2001, Paediatric respiratory reviews.
[133] W. Stenson,et al. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.
[134] J. Haeggström,et al. Molecular and catalytic properties of three rat leukotriene C(4) synthase homologs. , 2003, Biochemical and biophysical research communications.
[135] U. V. von Andrian,et al. Bltr Mediates Leukotriene B4–Induced Chemotaxis and Adhesion and Plays a Dominant Role in Eosinophil Accumulation in a Murine Model of Peritonitis , 2000, The Journal of experimental medicine.
[136] S. Dahlén,et al. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[137] O. Werz,et al. Extracellular signal‐regulated kinases phosphorylate 5lipoxygenase and stimulate 5‐lipoxygenase product formation in leukocytes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[138] W. Cunliffe,et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. , 2003, Archives of dermatology.
[139] A. Castonguay,et al. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. , 1998, Carcinogenesis.
[140] O. Werz,et al. Phosphorylation‐ and stimulus‐dependent inhibition of cellular 5‐lipoxygenase activity by nonredox‐type inhibitors , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[141] J. Ghosh. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. , 2004, Biochemical and biophysical research communications.
[142] H. Friess,et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. , 2002, The American journal of pathology.
[143] T. Hori,et al. Leukotriene B4 Receptor and the Function of Its Helix 8* , 2005, Journal of Biological Chemistry.
[144] R. D. Dyer,et al. 5-lipoxygenase inhibitory activity of zileuton. , 1991, The Journal of pharmacology and experimental therapeutics.
[145] J. Bouska,et al. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. , 1995, Journal of medicinal chemistry.
[146] T. Moody,et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. , 1996, The Journal of clinical investigation.
[147] Diana Murray,et al. Molecular Basis of the Specific Subcellular Localization of the C2-like Domain of 5-Lipoxygenase* , 2002, The Journal of Biological Chemistry.
[148] Takao Shimizu,et al. Stress-induced nuclear export of 5-lipoxygenase. , 2005, Biochemical and biophysical research communications.
[149] B. Koller,et al. Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deficient Mice , 1997, The Journal of experimental medicine.
[150] G. Landberg,et al. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. , 2003, Gastroenterology.
[151] D. Kerr,et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[152] J. Salmon,et al. Selective inhibition of arachidonate 5‐lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo , 1988, British journal of pharmacology.
[153] C. Myers,et al. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[154] T. Lewis,et al. 5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. , 2004, Bioorganic & medicinal chemistry letters.
[155] Jun Jiang,et al. LTB4 Can Directly Stimulate Human Osteoclast Formation from PBMC Independent of RANKL , 2005, Artificial cells, blood substitutes, and immobilization biotechnology.
[156] J. Mancini,et al. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. , 2006, The Biochemical journal.
[157] D. Riendeau,et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. , 1992, Canadian journal of physiology and pharmacology.
[158] Letts Lg. Leukotrienes: role in cardiovascular physiology. , 1987 .
[159] L. Bonewald,et al. Avian Osteoclast Cells are Stimulated to Resorb Calcified Matrices by and Possess Receptors for Leukotriene B4 , 1999, Calcified Tissue International.
[160] P. Vickers,et al. 5-Lipoxygenase-activating protein (FLAP). , 1995, Journal of lipid mediators and cell signalling.
[161] H. Vinters,et al. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[162] H. Showell,et al. Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[163] S. Charleson,et al. 5‐lipoxygenase‐activating protein is an arachidonate binding protein , 1993, FEBS letters.
[164] D. Steinhilber,et al. Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation. , 2000, Biochemical and biophysical research communications.
[165] R. McMillan,et al. Designing therapeutically effective 5-lipoxygenase inhibitors. , 1992, Trends in pharmacological sciences.
[166] G. Freeman,et al. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[167] O. Werz,et al. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds , 2005 .
[168] X. Ding,et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. , 1999, Biochemical and biophysical research communications.
[169] K. Kashfi,et al. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. , 1996, Biochimica et biophysica acta.
[170] K. Entian,et al. The 5-Lipoxygenase Promoter Is Regulated by DNA Methylation* , 2002, The Journal of Biological Chemistry.
[171] S. Dahlén,et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.
[172] T. Abram,et al. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. , 1994, European journal of pharmacology.
[173] A. Wendel,et al. Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. , 1993, The Journal of biological chemistry.
[174] C. Funk. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. , 1996, Biochimica et biophysica acta.
[175] S. McColl,et al. Studies on the activation of human neutrophil 5-lipoxygenase induced by natural agonists and Ca2+ ionophore A23187. , 1991, The Biochemical journal.
[176] E. Lobos,et al. Chemotactic activity in inflammatory bowel disease , 1987, Digestive Diseases and Sciences.
[177] K. Austen,et al. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[178] R. McMillan,et al. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. , 1992, Journal of medicinal chemistry.
[179] J. Kemp. Recent Advances in the Management of Asthma Using Leukotriene Modifiers , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.
[180] J. Ghosh. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. , 2003, Biochemical and biophysical research communications.
[181] R. Dziak,et al. Effects of leukotrienes on osteoblastic cell proliferation , 1991, Calcified Tissue International.
[182] D. Steinhilber,et al. Serum factors regulate 5-lipoxygenase activity in maturating HL60 cells. , 1993, Biochimica et biophysica acta.
[183] S. Ludwin,et al. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions , 2001, Journal of Neuroimmunology.
[184] T. Adrian,et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. , 2002, Molecular cancer therapeutics.
[185] Jilly F. Evans,et al. Identification and isolation of a membrane protein necessary for leukotriene production , 1990, Nature.
[186] D. Riendeau,et al. Cellular Oxygenation of 12-Hydroxyeicosatetraenoic Acid and 15-Hydroxyeicosatetraenoic Acid by 5-Lipoxygenase Is Stimulated by 5-Lipoxygenase-activating Protein* , 1998, The Journal of Biological Chemistry.
[187] T. Hullinger,et al. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. , 2005, European journal of pharmacology.
[188] L. Bonewald,et al. 5-Lipoxygenase metabolites inhibit bone formation in vitro. , 1998, Endocrinology.
[189] R. de Caterina,et al. Leukotriene B4 production in human atherosclerotic plaques. , 1988, Biomedica biochimica acta.
[190] R. Haggitt,et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. , 1997, Gastroenterology.
[191] J. Suttles,et al. Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[192] S. Soddu,et al. 5‐Lipoxygenase antagonizes genotoxic stress‐induced apoptosis by altering p53 nuclear trafficking , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[193] B. Pace,et al. Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. , 2004, Blood.
[194] D. Gudbjartsson,et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. , 2005, Journal of the American Medical Association (JAMA).
[195] J. Falgueyret,et al. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. , 1994, Journal of medicinal chemistry.
[196] C. Woo,et al. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation , 2004, Oncogene.
[197] Zhihua Liu,et al. The deregulation of arachidonic acid metabolism‐related genes in human esophageal squamous cell carcinoma , 2003, International journal of cancer.
[198] S. Laufer,et al. The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase , 2001, InflammoPharmacology.
[199] C. Shapleigh,et al. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. , 1980, The Journal of clinical investigation.
[200] J. Kremer,et al. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. , 1992, The Journal of rheumatology.
[201] T. Lewis,et al. 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. , 2005, Bioorganic & medicinal chemistry letters.
[202] L. Dubé,et al. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. , 1997, Gastroenterology.